The Lancet

Graham Watt,Rita Giacaman,Huda Zurayk,Espen Bjertness,Gerd Holmboe-Ottesen,Hala Ghattas,Iman Nuwayhid,Jennifer Leaning,John S Yudkin,Khamis Elessi,Richard Sullivan,Rima Afifi,Yousef S Khader,Harry S Shannon

doi : 10.1016/S0140-6736(21)00185-9

VOLUME 397, ISSUE 10274, P579, FEBRUARY 13, 2021

خرید پکیج و مشاهده آنلاین مقاله

COVID-19 in Brazil: far beyond biopolitics

Rafael Dall'Alba,Cristianne Famer Rocha,Roberta de Pinho Silveira,Liciane da Silva Costa Dresch,Luciana Ara?jo Vieira,Marco André German?

doi : 10.1016/S0140-6736(21)00202-6

VOLUME 397, ISSUE 10274, P579-580, FEBRUARY 13, 2021

خرید پکیج و مشاهده آنلاین مقاله

Progress towards inclusive blood donation

Graham McIlroy

doi : 10.1016/S0140-6736(21)00199-9

VOLUME 397, ISSUE 10274, P580, FEBRUARY 13, 2021

خرید پکیج و مشاهده آنلاین مقاله

Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme

Ruth E Langley,Duncan C Gilbert,Trinh Duong,Noel W Clarke,Matthew Nankivell,Stuart D Rosen,Stephen Mangar,Archie Macnair,Subramanian Kanaga Sundaram,Marc E Laniado,Sanjay Dixit,Sanjeev Madaan,Caroline Manetta,Alvan Pope,Christopher D Scrase,Stephen Mckay,Iqtedar A Muazzam,Gerald N Collins,Jane Worlding,Simon T Williams,Edgar Paez,Angus Robinson,Jonathan McFarlane,John V Deighan,John Marshall,Silvia Forcat,Melanie Weiss,Roger Kockelbergh,Abdulla Alhasso,Howard Kynaston,Mahesh Parmar

doi : 10.1016/S0140-6736(21)00100-8

VOLUME 397, ISSUE 10274, P581-591, FEBRUARY 13, 2021

Androgen suppression is a central component of prostate cancer management but causes substantial long-term toxicity. Transdermal administration of oestradiol (tE2) circumvents first-pass hepatic metabolism and, therefore, should avoid the cardiovascular toxicity seen with oral oestrogen and the oestrogen-depletion effects seen with luteinising hormone releasing hormone agonists (LHRHa). We present long-term cardiovascular follow-up data from the Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.

خرید پکیج و مشاهده آنلاین مقاله

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer,Saadettin Kilickap,Mahmut Gümü?,Igor Bondarenko,Mustafa ?zgüro?lu,Miranda Gogishvili,Haci M Turk,Irfan Cicin,Dmitry Bentsion,Oleg Gladkov,Philip Clingan,Virote Sriuranpong,Naiyer Rizvi,Bo Gao,Siyu Li,Sue Lee,Kristina McGuire,Chieh-I Chen,Tamta Makharadze,Semra Paydas,Marina Nechaeva,Frank Seebach,David M Weinreich,George D Yancopoulos,Giuseppe Gullo,Israel Lowy,Petra Rietschel

doi : 10.1016/S0140-6736(21)00228-2

VOLUME 397, ISSUE 10274, P592-604, FEBRUARY 13, 2021

We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50%.

خرید پکیج و مشاهده آنلاین مقاله

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group

doi : 10.1016/S0140-6736(21)00149-5

VOLUME 397, ISSUE 10274, P605-612, FEBRUARY 13, 2021

Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.

خرید پکیج و مشاهده آنلاین مقاله

A vertebral artery halo sign indicates giant cell arteritis affecting the posterior circulation of the brain

Roald A Lambrechts,Maarten Uyttenboogaart,Gea Drost

doi : 10.1016/S0140-6736(21)00248-8

VOLUME 397, ISSUE 10274, E6, FEBRUARY 13, 2021

خرید پکیج و مشاهده آنلاین مقاله

Adrenal insufficiency

Eystein S Husebye,Simon H Pearce,Nils P Krone,Olle K?mpe

doi : 10.1016/S0140-6736(21)00136-7

VOLUME 397, ISSUE 10274, P613-629, FEBRUARY 13, 2021

Adrenal insufficiency can arise from a primary adrenal disorder, secondary to adrenocorticotropic hormone deficiency, or by suppression of adrenocorticotropic hormone by exogenous glucocorticoid or opioid medications. Hallmark clinical features are unintentional weight loss, anorexia, postural hypotension, profound fatigue, muscle and abdominal pain, and hyponatraemia. Additionally, patients with primary adrenal insufficiency usually develop skin hyperpigmentation and crave salt. Diagnosis of adrenal insufficiency is usually delayed because the initial presentation is often non-specific; physician awareness must be improved to avoid adrenal crisis. Despite state-of-the-art steroid replacement therapy, reduced quality of life and work capacity, and increased mortality is reported in patients with primary or secondary adrenal insufficiency. Active and repeated patient education on managing adrenal insufficiency, including advice on how to increase medication during intercurrent illness, medical or dental procedures, and profound stress, is required to prevent adrenal crisis, which occurs in about 50% of patients with adrenal insufficiency after diagnosis. It is good practice for physicians to provide patients with a steroid card, parenteral hydrocortisone, and training for parenteral hydrocortisone administration, in case of vomiting or severe illness. New modes of glucocorticoid delivery could improve the quality of life in some patients with adrenal insufficiency, and further advances in oral and parenteral therapy will probably emerge in the next few years.

خرید پکیج و مشاهده آنلاین مقاله

The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing

Maria Elisa Mancuso,Johnny N Mahlangu,Steven W Pipe

doi : 10.1016/S0140-6736(20)32722-7

VOLUME 397, ISSUE 10274, P630-640, FEBRUARY 13, 2021

Congenital haemophilia A (factor VIII deficiency) and B (factor IX deficiency) are X-linked bleeding disorders. Replacement therapy has been the cornerstone of the management of haemophilia, aiming to reduce the mortality and morbidity of chronic crippling arthropathy. Frequent intravenous injections are burdensome and costly for patients, consequently with poor adherence and restricted access to therapy for many patients worldwide. Bioengineered clotting factors with enhanced pharmacokinetic profiles can reduce the burden of treatment. However, replacement therapy is associated with a risk for inhibitor development that adversely affects bleeding prevention and outcomes. Novel molecules that are subcutaneously delivered provide effective prophylaxis in the presence or absence of inhibitors, either substituting for the procoagulant function of clotting factors (eg, emicizumab) or targeting the natural inhibitors of coagulation (ie, antithrombin, tissue factor pathway inhibitor, or activated protein C). The ultimate goal of haemophilia treatment would be a phenotypical cure achievable with gene therapy, currently under late phase clinical investigation.

خرید پکیج و مشاهده آنلاین مقاله